PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11953891-5 2002 Cytokine-induced release of granulocyte-macrophage-colony stimulating factor, granulocyte-colony stimulating factor and macrophage-colony stimulating factor was significantly increased by cisplatin and 6-mercaptopurine. Cisplatin 188-197 colony stimulating factor 3 Homo sapiens 78-115 11865633-5 2002 The influence on the actual CDDP dose was observed with or without use of G-CSF or by recommended dose of CDDP, while no influence by 5-HT3 antagonist was observed. Cisplatin 28-32 colony stimulating factor 3 Homo sapiens 74-79 11181665-12 2001 CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF. Cisplatin 60-69 colony stimulating factor 3 Homo sapiens 145-150 11843253-1 2001 BACKGROUND: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support. Cisplatin 60-69 colony stimulating factor 3 Homo sapiens 151-156 11336465-0 2001 A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Cisplatin 20-29 colony stimulating factor 3 Homo sapiens 61-98 11336465-1 2001 The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Cisplatin 71-80 colony stimulating factor 3 Homo sapiens 135-140 11115564-0 2001 Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer. Cisplatin 22-31 colony stimulating factor 3 Homo sapiens 59-64 11006039-0 2000 Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer. Cisplatin 0-9 colony stimulating factor 3 Homo sapiens 43-48 11735678-14 2001 In two large head-to-head comparative clinical trials, paclitaxel plus cisplatin was associated with significantly greater response rates than cisplatin in combination with either teniposide or etoposide, and a survival advantage was shown for paclitaxel plus cisplatin (with or without G-CSF) over etoposide plus cisplatin. Cisplatin 71-80 colony stimulating factor 3 Homo sapiens 287-292 10561191-0 1999 Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. Cisplatin 198-207 colony stimulating factor 3 Homo sapiens 27-64 10873410-9 2000 CONCLUSION: The combination of paclitaxel with cisplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium. Cisplatin 47-56 colony stimulating factor 3 Homo sapiens 62-67 11016746-0 2000 Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. Cisplatin 0-9 colony stimulating factor 3 Homo sapiens 59-64 10355583-0 1999 Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Cisplatin 0-9 colony stimulating factor 3 Homo sapiens 58-63 10210543-6 1999 When cisplatin was added to this regimen, the observed myelosuppression necessitated the addition of granulocyte colony-stimulating factor. Cisplatin 5-14 colony stimulating factor 3 Homo sapiens 101-138 10071262-8 1999 G-CSF support permitted further dose escalation of cisplatin and topotecan. Cisplatin 51-60 colony stimulating factor 3 Homo sapiens 0-5 10321506-0 1999 A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cisplatin 46-55 colony stimulating factor 3 Homo sapiens 79-116 9923557-1 1999 PURPOSE: To investigate the activity of docetaxel and granulocyte colony-stimulating factor support (G-CSF) in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with cisplatin. Cisplatin 193-202 colony stimulating factor 3 Homo sapiens 54-99 9923557-1 1999 PURPOSE: To investigate the activity of docetaxel and granulocyte colony-stimulating factor support (G-CSF) in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with cisplatin. Cisplatin 193-202 colony stimulating factor 3 Homo sapiens 101-106 9887248-2 1998 The purpose of this phase I study was to determine the maximal dose of doxorubicin that could be added to standard doses of paclitaxel and cisplatin with G-CSF support. Cisplatin 139-148 colony stimulating factor 3 Homo sapiens 154-159 9427795-0 1997 A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study. Cisplatin 49-58 colony stimulating factor 3 Homo sapiens 64-101 9694607-0 1998 Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. Cisplatin 18-27 colony stimulating factor 3 Homo sapiens 48-53 9694607-24 1998 CONCLUSIONS: Weekly paclitaxel and cisplatin with G-CSF support is an active and particularly well tolerated treatment for patients with either unpretreated or pretreated metastatic breast cancer. Cisplatin 35-44 colony stimulating factor 3 Homo sapiens 50-55 9602269-14 1998 CONCLUSIONS: The docetaxel-cisplatin combination is an active regimen in advanced NSCLC, but hematologic toxicity remains high despite the prophylactic use of G-CSF. Cisplatin 27-36 colony stimulating factor 3 Homo sapiens 159-164 9053499-5 1997 With G-CSF support, one of three patients experienced both dose-limiting mucositis and fatal neutropenic sepsis at a dose of paclitaxel 180 mg/m2/96 hours and cisplatin 80 mg/m2. Cisplatin 159-168 colony stimulating factor 3 Homo sapiens 5-10 9167751-0 1997 Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP). Cisplatin 166-175 colony stimulating factor 3 Homo sapiens 32-69 9043028-0 1997 Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Cisplatin 27-36 colony stimulating factor 3 Homo sapiens 42-79 8629035-6 1996 Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination. Cisplatin 92-101 colony stimulating factor 3 Homo sapiens 121-158 8841050-16 1996 In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma. Cisplatin 83-87 colony stimulating factor 3 Homo sapiens 206-211 8841050-16 1996 In conclusion, adverse reactions caused by the combination therapy with CPT-11 and CDDP (CPT-11: 50-60 mg/m2 on days 1, 8 and 15, CDDP: 50-60 mg/m2 on day 1) can be relieved by short term administration of G-CSF and it is suggested that the combination therapy may be effective in treating ovarian carcinoma. Cisplatin 130-134 colony stimulating factor 3 Homo sapiens 206-211 8954183-0 1996 Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma. Cisplatin 159-168 colony stimulating factor 3 Homo sapiens 28-65 8774656-0 1996 Sequential granulocyte colony-stimulating factor increases cisplatin cytotoxicity in human epithelial ovarian cancer cell lines. Cisplatin 59-68 colony stimulating factor 3 Homo sapiens 11-48 8774656-5 1996 Simultaneous G-CSF decreased cisplatin cytotoxicity in five cell lines (7-45%). Cisplatin 29-38 colony stimulating factor 3 Homo sapiens 13-18 8774656-6 1996 Sequential G-CSF increased cisplatin cytotoxicity in all six cell lines (5-108%). Cisplatin 27-36 colony stimulating factor 3 Homo sapiens 11-16 8774656-8 1996 Simultaneous G-CSF may decrease cisplatin cytotoxicity, while sequential G-CSF appears to increase cisplatin cytotoxicity. Cisplatin 99-108 colony stimulating factor 3 Homo sapiens 73-78 8629035-6 1996 Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination. Cisplatin 241-250 colony stimulating factor 3 Homo sapiens 121-158 8742097-1 1996 It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg. Cisplatin 178-187 colony stimulating factor 3 Homo sapiens 47-84 8742097-1 1996 It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg. Cisplatin 178-187 colony stimulating factor 3 Homo sapiens 86-91 1384952-0 1992 Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. Cisplatin 91-100 colony stimulating factor 3 Homo sapiens 131-168 7474409-1 1995 A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer. Cisplatin 48-57 colony stimulating factor 3 Homo sapiens 115-152 7474409-1 1995 A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer. Cisplatin 48-57 colony stimulating factor 3 Homo sapiens 154-159 7525886-17 1994 CONCLUSION: The addition of cisplatin to 5-FU, HU, and concomitant radiotherapy is feasible using G-CSF. Cisplatin 28-37 colony stimulating factor 3 Homo sapiens 98-103 7521906-1 1994 PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles. Cisplatin 99-108 colony stimulating factor 3 Homo sapiens 141-178 7521906-1 1994 PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles. Cisplatin 99-108 colony stimulating factor 3 Homo sapiens 180-185 7907208-9 1994 Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor. Cisplatin 84-93 colony stimulating factor 3 Homo sapiens 175-212 7692001-5 1993 RESULTS: The development of a severe peripheral neuropathy and/or severe myalgias precluded the chronic administration of Taxol and cisplatin with G-CSF at doses greater than 250 mg/m2 and 75 mg/m2, respectively. Cisplatin 132-141 colony stimulating factor 3 Homo sapiens 147-152 7692001-11 1993 CONCLUSION: Taxol and cisplatin doses of 250 mg/m2 and 75 mg/m2, respectively, can be administered repetitively with G-CSF to untreated and minimally pretreated patients. Cisplatin 22-31 colony stimulating factor 3 Homo sapiens 117-122 7685138-0 1993 [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy]. Cisplatin 168-179 colony stimulating factor 3 Homo sapiens 29-66 7685138-1 1993 We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy. Cisplatin 223-234 colony stimulating factor 3 Homo sapiens 74-111 8749950-0 1995 Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study. Cisplatin 66-75 colony stimulating factor 3 Homo sapiens 100-137 8583722-6 1995 Chemotherapy with vindesine, ifosfamide, and cisplatin resulted in shrinkage of the gingival mass, and a decrease in the G-CSF level to 66 pg/ml. Cisplatin 45-54 colony stimulating factor 3 Homo sapiens 121-126 7530173-10 1995 The addition of GCSF during weeks 1, 3, and 4 allowed for escalation of cisplatin to 100 mg/m2 during weeks 1 and 2, with a decreased dose of IFN at 2.5 MU/m2 per day to avoid renal toxicity. Cisplatin 72-81 colony stimulating factor 3 Homo sapiens 16-20 7530173-21 1995 (2) GCSF can be safely administered and provides effective support of neutrophils when administered simultaneously with IFN, cisplatin, and chest radiotherapy. Cisplatin 125-134 colony stimulating factor 3 Homo sapiens 4-8 7513844-1 1994 Recombinant human granulocyte colony-stimulating factor (rG-CSF) was used for the amelioration of neutropenia caused by cisplatin-based chemotherapy in head and neck cancer patients. Cisplatin 120-129 colony stimulating factor 3 Homo sapiens 18-55 7512280-0 1994 Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract. Cisplatin 125-134 colony stimulating factor 3 Homo sapiens 28-65 7527732-0 1994 M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen. Cisplatin 50-59 colony stimulating factor 3 Homo sapiens 66-103 7512356-0 1994 A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Cisplatin 65-69 colony stimulating factor 3 Homo sapiens 94-131 7692001-0 1993 Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. Cisplatin 50-59 colony stimulating factor 3 Homo sapiens 65-102 7692928-0 1993 Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Cisplatin 189-198 colony stimulating factor 3 Homo sapiens 65-102 8385969-1 1993 This study was aimed at preventing of chemotherapy-induced neutropenia and improving the therapeutic result by reducing the cycle length of cisplatin (25 mg/m2/day, 5-day continuous infusion) and vindesine (3 mg/m2, bolus, days 1 and 8) (PiV) through the use of recombinant human granulocyte colony-stimulating factor (rG-CSF) (2-5 micrograms/kg/day, subcutaneous, days 6-21) for non-small cell lung carcinoma (NSCLC). Cisplatin 140-149 colony stimulating factor 3 Homo sapiens 280-317 1281446-0 1992 The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer. Cisplatin 119-128 colony stimulating factor 3 Homo sapiens 11-48 1381342-0 1992 Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens. Cisplatin 126-135 colony stimulating factor 3 Homo sapiens 0-37 28093087-11 2017 On univariate analysis, cisplatin based chemotherapy, presence of central venous catheter, female gender, poor performance status, high risk stratification according to the Khorana model and use of granulocyte colony stimulating factor were all significantly associated with the development of VTE. Cisplatin 24-33 colony stimulating factor 3 Homo sapiens 198-235 33590721-1 2021 BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP). Cisplatin 275-284 colony stimulating factor 3 Homo sapiens 142-179 33147611-0 2021 A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Cisplatin 121-130 colony stimulating factor 3 Homo sapiens 34-71 33147611-1 2021 BACKGROUND: An exploratory study was designed to evaluate the efficacy of granulocyte colony stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer. Cisplatin 162-171 colony stimulating factor 3 Homo sapiens 74-111 33147611-12 2021 CONCLUSIONS: Granulocyte colony stimulating factor support including secondary prophylactic usage may be feasible for maintaining the intensity of docetaxel, cisplatin and 5-fluorouracil chemotherapy in patients with oesophageal cancer. Cisplatin 158-167 colony stimulating factor 3 Homo sapiens 13-50 31742349-8 2020 Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis. Cisplatin 203-212 colony stimulating factor 3 Homo sapiens 30-67 31742349-8 2020 Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from cisplatin-induced apoptosis. Cisplatin 203-212 colony stimulating factor 3 Homo sapiens 69-74 29948238-1 2018 BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. Cisplatin 170-179 colony stimulating factor 3 Homo sapiens 49-86 29948238-1 2018 BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. Cisplatin 170-179 colony stimulating factor 3 Homo sapiens 88-93 24821366-0 2014 Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Cisplatin 109-118 colony stimulating factor 3 Homo sapiens 29-34 26666576-7 2015 The depletion of MDSC via splenectomy or the administration of anti-Gr-1 antibody sensitized G-CSF-producing cervical cancer to cisplatin. Cisplatin 128-137 colony stimulating factor 3 Homo sapiens 93-98 20437856-1 2010 BACKGROUND: In 1995, we designed and carried out a pilot study on the combination of cisplatin + high dose epirubicin + vinorelbine with granulocyte-colony-stimulating factor support for the induction treatment of unresectable stage IIIAN2 and wet IIIB non-small-cell lung cancer. Cisplatin 85-94 colony stimulating factor 3 Homo sapiens 137-174 24625457-0 2014 Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience. Cisplatin 58-67 colony stimulating factor 3 Homo sapiens 20-25 20708854-15 2011 CONCLUSIONS: One-cycle full-dose docetaxel/cisplatin induction chemotherapy with recombinant human granulocyte colony-stimulating factor followed by pulsed low-dose docetaxel CRT is promising with regard to its antitumor activity, low rates of distant failure, and low toxicity, suggesting that this regimen deserves further investigation. Cisplatin 43-52 colony stimulating factor 3 Homo sapiens 99-136 23749899-8 2013 Under treatment with low concentrations of 5-fluorouracil and cisplatin, all examined cell lines showed an increasing secretion of the cytokines IL-6 and G-CSF. Cisplatin 62-71 colony stimulating factor 3 Homo sapiens 154-159 22993377-18 2012 In conclusion, this modified regimen of docetaxel-cisplatin-capecitabine appears to have comparable efficacy with that reported for the reference regimen, with acceptable toxicity when G-CSF support is provided. Cisplatin 50-59 colony stimulating factor 3 Homo sapiens 185-190 20300587-3 2010 Here, we report a case of large cisplatin overdose, successfully managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other supportive care. Cisplatin 32-41 colony stimulating factor 3 Homo sapiens 116-153 20300587-3 2010 Here, we report a case of large cisplatin overdose, successfully managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other supportive care. Cisplatin 32-41 colony stimulating factor 3 Homo sapiens 155-160 19619443-13 2009 In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p<0.05). Cisplatin 148-151 colony stimulating factor 3 Homo sapiens 57-94 19218307-0 2009 Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Cisplatin 20-29 colony stimulating factor 3 Homo sapiens 57-62 19619443-13 2009 In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p<0.05). Cisplatin 148-151 colony stimulating factor 3 Homo sapiens 96-101 18697197-4 2008 Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL-6, CXCL8, CCL2, CCL5, BFGF, G-CSF and VEGF. Cisplatin 46-55 colony stimulating factor 3 Homo sapiens 143-148 17094396-15 2006 In conclusion, the combination of docetaxel plus cisplatin appears to be a moderately effective regimen with acceptable toxicity when G-CSF support is provided. Cisplatin 49-58 colony stimulating factor 3 Homo sapiens 134-139 15358478-0 2004 A patient with granulocyte-colony stimulating factor-producing endometrial cancer who responded to high-dose cisplatin, cyclophosphamide and adriamycin. Cisplatin 109-118 colony stimulating factor 3 Homo sapiens 15-52 14665607-0 2004 Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. Cisplatin 14-23 colony stimulating factor 3 Homo sapiens 29-66 14665607-0 2004 Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. Cisplatin 14-23 colony stimulating factor 3 Homo sapiens 68-73